olanzapine pamoate depot — Competitive Intelligence Brief

olanzapine pamoate depot (olanzapine pamoate depot) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry Small molecule

Target snapshot

olanzapine pamoate depot (olanzapine pamoate depot) — Eli Lilly and Company. Olanzapine pamoate depot is a long-acting intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
olanzapine pamoate depot TARGET	olanzapine pamoate depot	Eli Lilly and Company	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Oral Olanzapine	Oral Olanzapine	Eli Lilly and Company	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
SAPHRIS	SAPHRIS	Sun Pharmaceutical Industries Limited	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Lithium carbonate + perospirone hydrochloride	Lithium carbonate + perospirone hydrochloride	Shanghai Mental Health Center	marketed	Mood stabilizer + atypical antipsychotic combination	Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone)
Quetiapine or Risperidone + Aripiprazole	Quetiapine or Risperidone + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
Quetiapine (drug)	Quetiapine (drug)	Medical University of Vienna	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Seroquel (quetiapine)	Seroquel (quetiapine)	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

1. Shanghai Mental Health Center · 10 drugs in this class
2. AstraZeneca · 6 drugs in this class
3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
5. Eli Lilly and Company · 4 drugs in this class
6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
7. Medical University of Vienna · 2 drugs in this class
8. Organon and Co · 2 drugs in this class
9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
10. H. Lundbeck A/S · 2 drugs in this class